Delivery Order SPE2DR25D2206-SPE2DR26F9BD2
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 10, 2025, for the supply of 36,000 units of Creon DR 100 strength capsules, with a ceiling value of $8,364.84 and an ultimate completion date of November 12, 2025. This firm fixed-price delivery order represents a non-competitive award under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules on November 3, 2025, with a ceiling value of $6,571.00 and an ultimate completion date of November 4, 2025. This competitively awarded, firm fixed-price delivery order was placed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The contract involves...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Creon DR 24,000 unit capsules (100 count) with a ceiling value of $2,262.52 and an ultimate completion date of August 11, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles, valued at $31,396.02. This firm fixed price delivery order, which represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX, valued at $999,999,999.00 through December 2026), was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 28, 2025, for 12,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles, with a ceiling value of $1,195.45. This is a firm fixed price delivery order with an ultimate completion date of October 29, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order valued at $5,717.04 to AmerisourceBergen Drug Corp for 24,000-unit capsules of Creon (pancreatic enzyme replacement therapy) on October 27, 2025, with completion targeted for October 28, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a routine pharmaceutical procurement to support federal medical supply needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered...
- The Defense Logistics Agency awarded a delivery order valued at $7,821.96 to AmerisourceBergen Drug Corp on November 5, 2025, for the supply of 36,000 unit capsules of Creon (pancrelipase) in 100-count bottles. This is a firm fixed price, competitively awarded contract with no set-aside designation, and performance will be completed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of November 6, 2025. The delivery order represents a child contract...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Creon DR 36,000 Unit Capsules in packages of 100 units. This competitive, non-set-aside contract is valued at $1,290.59 with firm fixed pricing and a completion date of August 8, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in Conshohocken, PA...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for 24,000 units of Creon DR 100s capsules valued at $7,245.28. The contract utilizes firm fixed price pricing with no set-aside designation, indicating competitive award through open competition. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of July 30, 2025. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Creon DR 36,000 unit capsules in 100-count packages, valued at $30,119.69. This competitively awarded, firm fixed-price delivery order was issued on June 2, 2025, with an ultimate completion date of June 3, 2025. The contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- SPE2DR25D2206Indefinite Delivery Contract
- SPE2DR25D2206-SPE2DR26F9BD2Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on November 10, 2025, for the supply of Creon DR 36,000 Unit Capsules (100 count) with a ceiling value of $9,698.05. This firm fixed price delivery order, with an ultimate completion date of November 12, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract involves no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement through its $999,999,999.00 prime IDC with DLA Troop Support Medical (designated SPE2DX) running through December 2026. The company's comprehensive pharmaceutical supply arrangement with the DLA supports military and veteran healthcare systems with brand-name and generic medications, specialty drugs, and medical supplies across multiple therapeutic domains. This delivery order for Creon DR, a pancreatic enzyme supplement, reflects the company's ongoing role in fulfilling pharmaceutical commodities for Defense Health Agency and other federal healthcare customers through competitive contracting mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.7k | 11/10/25 |